Raymond James Financial Inc. Grows Stock Holdings in Organon & Co. $OGN

Raymond James Financial Inc. grew its holdings in Organon & Co. (NYSE:OGN) by 13.2% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 318,128 shares of the company’s stock after acquiring an additional 37,018 shares during the period. Raymond James Financial Inc. owned about 0.12% of Organon & Co. worth $4,737,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also made changes to their positions in the business. Hsbc Holdings PLC lifted its holdings in shares of Organon & Co. by 13.9% in the fourth quarter. Hsbc Holdings PLC now owns 13,922 shares of the company’s stock worth $208,000 after buying an additional 1,703 shares in the last quarter. NBC Securities Inc. raised its stake in Organon & Co. by 111,262.5% during the first quarter. NBC Securities Inc. now owns 8,909 shares of the company’s stock valued at $132,000 after purchasing an additional 8,901 shares in the last quarter. Sequoia Financial Advisors LLC raised its position in shares of Organon & Co. by 42.2% during the 1st quarter. Sequoia Financial Advisors LLC now owns 19,392 shares of the company’s stock valued at $289,000 after buying an additional 5,758 shares in the last quarter. M&T Bank Corp raised its position in shares of Organon & Co. by 3.4% during the 1st quarter. M&T Bank Corp now owns 55,990 shares of the company’s stock valued at $833,000 after buying an additional 1,854 shares in the last quarter. Finally, Cetera Investment Advisers raised its position in shares of Organon & Co. by 62.7% during the 4th quarter. Cetera Investment Advisers now owns 76,005 shares of the company’s stock valued at $1,134,000 after buying an additional 29,287 shares in the last quarter. 77.43% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have recently issued reports on OGN shares. BNP Paribas upgraded shares of Organon & Co. to a “strong-buy” rating in a research report on Thursday, May 22nd. Piper Sandler decreased their price objective on Organon & Co. from $24.00 to $18.00 and set an “overweight” rating on the stock in a research report on Thursday, May 15th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $17.33.

Organon & Co. Stock Performance

OGN stock opened at $10.37 on Friday. The company has a quick ratio of 1.13, a current ratio of 1.65 and a debt-to-equity ratio of 11.98. The business’s fifty day simple moving average is $9.59 and its two-hundred day simple moving average is $11.06. Organon & Co. has a twelve month low of $8.01 and a twelve month high of $21.25. The firm has a market cap of $2.69 billion, a price-to-earnings ratio of 3.85, a PEG ratio of 0.88 and a beta of 0.60.

Organon & Co. (NYSE:OGN) last released its earnings results on Tuesday, August 5th. The company reported $1.00 earnings per share for the quarter, topping analysts’ consensus estimates of $0.94 by $0.06. The business had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.55 billion. Organon & Co. had a return on equity of 163.88% and a net margin of 11.15%.The business’s revenue was down .8% compared to the same quarter last year. During the same quarter last year, the firm posted $1.12 earnings per share. Organon & Co. has set its FY 2025 guidance at EPS. Analysts predict that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 11th. Stockholders of record on Friday, August 15th will be given a dividend of $0.02 per share. The ex-dividend date of this dividend is Friday, August 15th. This represents a $0.08 dividend on an annualized basis and a dividend yield of 0.8%. Organon & Co.’s dividend payout ratio (DPR) is 2.97%.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.